Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.
- Population:
- Cisgender Men
- Gay and Bisexual Men Who Have Sex with Men
- Transgender Women
- Topics:
- Tracking and Translating the Field
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!